Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 117 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: electroporation therapy Clear all

Conditions: Pancreatic Adenocarcinoma, Liver Metastases
Interventions: Floxuridine (FUDR), Hepatic Artery Infusion Pump, Heparinized Saline; Drug · Device
Lead sponsor: Corewell Health West; Other
Eligibility: 18 Years to 75 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: Venezuelan Equine Encephalitis Virus Infection
Interventions: Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate, 0.9% saline placebo; Biological · Other
Lead sponsor: Ichor Medical Systems Incorporated; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: San Diego, California

Conditions: Hantaan Virus Disease, Puumala Virus
Interventions: Hantaan virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intradermal Delivery (ID), Hantaan virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intramuscular Delivery (IM), Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID), Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intramuscular Delivery (IM), Hantaan/Puumala (HTNV/PUUV) virus vaccines - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID), Hantaan/Puumala (HTNV/PUUV virus vaccines - Using the TriGrid Delivery System (TDS) for Intramusular Delivery (IM); Combination Product
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 49 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Head and Neck Squamous Cell Cancer
Interventions: INO-3112, CELLECTRA™-5P; Biological · Device
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL
Interventions: VGX-3100, Placebo, Electroporation (EP); Biological · Device
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 22
States / cities: Mesa, Arizona • Scottsdale, Arizona • Tucson, Arizona + 18 more

Conditions: Pancreas Cancer
Interventions: NanoKnife procedure; Other
Lead sponsor: Methodist Health System; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Papillomavirus Infections
Interventions: VGX-3100; Biological
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 3
States / cities: Winston-Salem, North Carolina • Hopwood, Pennsylvania • Philadelphia, Pennsylvania

Conditions: Melanoma (Skin Cancer), Advanced Melanoma, Metastatic Melanoma, Skin Cancer
Interventions: iSCIB1+, Nivolumab & Ipilimumab, Placebo; Biological · Drug · Other
Lead sponsor: Scancell Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Healthy
Interventions: VGX-3400X; Biological
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Overland Park, Kansas • Rockville, Maryland

Conditions: Triple Negative Breast Cancer, Triple-Negative Breast Cancer, Triple Negative Breast Neoplasms
Interventions: Personalized polyepitope DNA vaccine; Biological
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL
Interventions: VGX-3100, Matched Placebo, CELLECTRA™-5PSP; Biological · Device
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 27
States / cities: Tucson, Arizona • Danbury, Connecticut • Newark, Delaware + 24 more

Conditions: Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), COVID-19 Disease
Interventions: INO-4800, CELLECTRA® 2000, Placebo; Drug · Device
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,307 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 16
States / cities: Chandler, Arizona • Phoenix, Arizona • Tempe, Arizona + 12 more

Conditions: Head and Neck Cancer
Interventions: Medpulser Electroporation with Bleomycin; Combination Product
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: San Diego, California

Conditions: Melanoma
Interventions: Tavo, Nivolumab, OncoSec Medical Electroporation Therapy System; Drug · Device
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Unmethylated Glioblastoma
Interventions: Personalized Neoantigen DNA vaccine, Retifanlimab, TDS-IM v 2.0 electroporation device; Biological · Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Healthy Volunteers
Interventions: INO-A002, CELLECTRA® 2000, Dengue Fever Antibodies (IgG); Biological · Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Human Papillomavirus (HPV)
Interventions: VGX-3100; Biological
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years to 46 Years · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Winston-Salem, North Carolina • Hopwood, Pennsylvania

Conditions: Breast Cancer, Breast Carcinoma, Malignant Neoplasm of Breast
Interventions: Mammaglobin-A DNA Vaccine, Optional biopsy; Biological · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Stage III Pancreatic Cancer
Interventions: SOC, NanoKnife System; Drug · Device
Lead sponsor: Angiodynamics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 532 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 14
States / cities: La Jolla, California • Gainesville, Florida • Miami, Florida + 10 more

Conditions: Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
Interventions: Globe Pulsed Field System; Device
Lead sponsor: Kardium Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 549 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 11
States / cities: Birmingham, Alabama • Jonesboro, Arkansas • San Francisco, California + 8 more

Conditions: Atrial Fibrillation (AF), Persistant Atrial Fibrillation, Paroxysmal AF
Interventions: Argá Medtech Coherent Sine-Burst Electroporation (CSE) Ablation System; Device
Lead sponsor: Arga Medtech SA; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 18
States / cities: Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 14 more

Conditions: Anal Neoplasm
Interventions: VGX-3100, CELLECTRA™ 5PSP; Biological · Device
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Chicago, Illinois • New York, New York

Conditions: Atrial Fibrillation (AF)
Interventions: Pulmonary Vein Isolation (PVI) without Left Atrial Posterior Wall Isolation (PWI), Pulmonary Vein Isolation (PVI) with Left Atrial Posterior Wall Isolation (PWI); Procedure
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Atrial Fibrillation
Interventions: Pulse Field Ablation; Device
Lead sponsor: Biosense Webster, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 362 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 30
States / cities: Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 23 more

Search by objective public record fields.

Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases

Study of a DNA-based Venezuelan Equine Encephalitis Virus DNA Vaccine Administered by Electroporation in Healthy Volunteers

Combination HTNV and PUUV DNA Vaccine

Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma

REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

Pancreatic Cancer & Surgical Resection

Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3

iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma

Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Electroporation in Healthy Adults

Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy

REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure

Study Using the Medpulser Electroporation System With Bleomycin to Treat Head and Neck Cancer

Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients

Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma

A Study of INO-A002 in Healthy Dengue Virus-naive Adults

Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100

Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy

A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer

Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation

Coherent Sine Burst Electroporation (CSE) Ablation System US IDE Study for Patients With Atrial Fibrillation

VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2

Comparative Effectiveness of Different Techniques for Repeat Ablation of Atrial Fibrillation

Assessment of Safety and Effectiveness in Treatment Management of Atrial Fibrillation With the BWI IRE Ablation System